# Lyell Immunopharma, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/lyell-immunopharma-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 27 | | Claims under review | 1 | | Evidence records | 9 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-16T13:52:54.339891+00:00 | | Last reviewed | 2026-10-16T13:52:54.339891+00:00 | ## Identity - Legal name: Lyell Immunopharma, Inc. - Display name: Lyell Immunopharma, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-17T03:38:03.342229+00:00 | | Completeness | 0.409 | | Record Quality | 0.846 | | Directors | 8 | | Committees | 6 | | Governance events | 20 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Clifford J. Friedman: Director. Status: current. Independent: true. Since: 2018-01-01. Committees: Audit (member); Audit; Compensation · Chair (member); Compensation (chair). claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5 - Elizabeth Nabel: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member); Audit; Nominating and Governance (member); Nominating and Governance (member). claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6 - Lynn Seely, M.D.: Director. Status: current. Independent: false. Since: 2021-01-01. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:7 - Martine Rothblatt, Ph.D., J.D., M.B.A.: Director. Status: current. Independent: true. Since: 2025-01-01. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:8 - Otis Brawley, M.D.: Director. Status: current. Independent: true. Since: 2021-01-01. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:9 - Richard Klausner, M.D.: Director. Status: current. Independent: false. Since: 2018-01-01. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:10 - Sumant Ramachandra, M.D., Ph.D.: Director. Status: current. Independent: true. Since: 2024-01-01. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:11 - William Rieflin: Director. Status: current. Independent: true. Since: 2020-01-01. Committees: Audit (chair); Audit · Chair; Compensation (member); Compensation (member). claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12 ## Committees - Audit (audit). Chair: William Rieflin. Members: William Rieflin (chair, current); Clifford J. Friedman (member, current); Elizabeth Nabel (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:audit - Audit · Chair; Compensation (audit). Chair: NOT_PUBLISHED. Members: William Rieflin (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:audit-chair-compensation - Audit; Compensation · Chair (audit). Chair: NOT_PUBLISHED. Members: Clifford J. Friedman (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:audit-compensation-chair - Audit; Nominating and Governance (audit). Chair: NOT_PUBLISHED. Members: Elizabeth Nabel (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:audit-nominating-and-governance - Compensation (compensation). Chair: Clifford J. Friedman. Members: Clifford J. Friedman (chair, current); William Rieflin (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:compensation - Nominating and Governance (nominating_governance). Chair: NOT_PUBLISHED. Members: Elizabeth Nabel (member, current). committee_id=alpha:committee:lyell-immunopharma-inc:nominating-and-governance ## Executive leadership - David Shook, M.D.: Chief Medical Officer. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:13 - Gary Lee, Ph.D.: Chief Scientific Officer. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:14 - Lynn Seely, M.D.: President, Chief Executive Officer and Director [CEO]. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:15 - Mark Meltz: General Counsel and Corporate Secretary [GC]. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:16 - Smital Shah: Chief Financial and Business Officer. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:17 - Stephen Hill: Chief Operating Officer [COO]. Status: current. claim_id=alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:18 ## Governance events - EXECUTIVE_APPOINTED: David Shook, M.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:16g2xhi1r6dzoe - EXECUTIVE_APPOINTED: Gary Lee, Ph.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:11nt6ty46p5p - CEO_CHANGED: Lynn Seely, M.D. executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1tnbau01qhwilo - GC_CHANGED: Mark Meltz executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1mxdlrc1b283ig - EXECUTIVE_APPOINTED: Smital Shah executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:urobrt8az3d7 - EXECUTIVE_APPOINTED: Stephen Hill executive of Lyell Immunopharma, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1oyeyyk1rdlrma - DIRECTOR_APPOINTED: Martine Rothblatt, Ph.D., J.D., M.B.A. seat on Lyell Immunopharma, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1lmln1pcl7kcp - DIRECTOR_APPOINTED: Sumant Ramachandra, M.D., Ph.D. seat on Lyell Immunopharma, Inc., effective 2024-01-01. Effective: 2024-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1qbnu6gyxi5k8 - DIRECTOR_APPOINTED: Elizabeth Nabel seat on Lyell Immunopharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1dpw14dqss3g7 - DIRECTOR_APPOINTED: Lynn Seely, M.D. seat on Lyell Immunopharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1pp7242vp9gbu - DIRECTOR_APPOINTED: Otis Brawley, M.D. seat on Lyell Immunopharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1iwagy417ryigc - COMMITTEE_CREATED: Audit; Nominating and Governance committee of Lyell Immunopharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:11lac2bgapn7f - COMMITTEE_MEMBER_ADDED: Elizabeth Nabel member of Audit; Nominating and Governance, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1nqvtlqonnc34 - DIRECTOR_APPOINTED: William Rieflin seat on Lyell Immunopharma, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:knovank0jbsf - COMMITTEE_CREATED: Audit · Chair; Compensation committee of Lyell Immunopharma, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:5j2tj1ffdla7 - COMMITTEE_MEMBER_ADDED: William Rieflin member of Audit · Chair; Compensation, effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:109pujn9s9omz - DIRECTOR_APPOINTED: Clifford J. Friedman seat on Lyell Immunopharma, Inc., effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1ora43oxx0oq6 - DIRECTOR_APPOINTED: Richard Klausner, M.D. seat on Lyell Immunopharma, Inc., effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1efdc2mgyd9xi - COMMITTEE_CREATED: Audit; Compensation · Chair committee of Lyell Immunopharma, Inc., effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1cmkcb6hgpmky - COMMITTEE_MEMBER_ADDED: Clifford J. Friedman member of Audit; Compensation · Chair, effective 2018-01-01. Effective: 2018-01-01. Detected: 2026-10-16T13:52:54.339891+00:00. event_id=alpha:event:transition:1tfne0q16gp3ry ## Scoped resources - `alpha://company/lyell-immunopharma-inc` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record - `alpha://company/lyell-immunopharma-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=identity - `alpha://company/lyell-immunopharma-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=corporate-structure - `alpha://company/lyell-immunopharma-inc/board` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=board - `alpha://company/lyell-immunopharma-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=committees - `alpha://company/lyell-immunopharma-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=leadership - `alpha://company/lyell-immunopharma-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=ownership - `alpha://company/lyell-immunopharma-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=financials - `alpha://company/lyell-immunopharma-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=capital-structure - `alpha://company/lyell-immunopharma-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=compensation - `alpha://company/lyell-immunopharma-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=governance - `alpha://company/lyell-immunopharma-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=shareholder-governance - `alpha://company/lyell-immunopharma-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=audit - `alpha://company/lyell-immunopharma-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=legal - `alpha://company/lyell-immunopharma-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=risk - `alpha://company/lyell-immunopharma-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=cyber - `alpha://company/lyell-immunopharma-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=ai-governance - `alpha://company/lyell-immunopharma-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=agents - `alpha://company/lyell-immunopharma-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=ecosystem - `alpha://company/lyell-immunopharma-inc/events` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=events - `alpha://company/lyell-immunopharma-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=relationships - `alpha://company/lyell-immunopharma-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=assessments - `alpha://company/lyell-immunopharma-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:20: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:william-rieflin","name":"William Rieflin"},"source_id":"board_seats"}` - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:21: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:catherine-friedman","name":"Clifford J. Friedman"},"source_id":"board_seats"}` - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:22: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:elizabeth-nabel","name":"Elizabeth Nabel"},"source_id":"board_seats"}` - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:24: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"chair","person":{"alpha_id":"alpha:person:catherine-friedman","name":"Clifford J. Friedman"},"source_id":"board_seats"}` - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:25: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:william-rieflin","name":"William Rieflin"},"source_id":"board_seats"}` - Claim alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:27: `{"kind":"committee_appointment","original_name":"Nominating and Governance","category":"nominating_governance","role":"member","person":{"alpha_id":"alpha:person:elizabeth-nabel","name":"Elizabeth Nabel"},"source_id":"board_seats"}` ## Leadership - Clifford J. Friedman: Director, Audit; Compensation · Chair. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:5. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Elizabeth Nabel: Director, Audit; Nominating and Governance. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:6. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Lynn Seely, M.D.: Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:7. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Martine Rothblatt, Ph.D., J.D., M.B.A.: Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:8. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Otis Brawley, M.D.: Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:9. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Richard Klausner, M.D.: Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:10. Valid from: 2018-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - Sumant Ramachandra, M.D., Ph.D.: Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:11. Valid from: 2024-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - William Rieflin: Director, Audit · Chair; Compensation. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:12. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7. - David Shook, M.D.: Chief Medical Officer. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:13. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:e4e1778b345e62bde7de98a4a5a81ef85040055ae32e0f8a8962d919b8db6bae. - Gary Lee, Ph.D.: Chief Scientific Officer. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:14. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:38d8832995f4cc3f87148dcbc7a1cdeec1e8280e4936cd4a2260980915404f64. - Lynn Seely, M.D.: President, Chief Executive Officer and Director. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:15. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:a8feb7f4a9483c84c5f543aa45dcb5607d017ed17bd5def0c5925e2c84251646. - Mark Meltz: General Counsel and Corporate Secretary. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:16. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:9def3689e80e3c3526608efc7c40f31eadbf1dc0d21c3d7ee72fbd9074cc775e. - Smital Shah: Chief Financial and Business Officer. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:17. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:3f372c75ae285ef6bb9b63df09092aa44753680a9d1dbfc41e3cfc53e87b372c. - Stephen Hill: Chief Operating Officer. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:leadership_role:18. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ed0feab478b28957f8d0a675bce18b4f21b00bcd083493cf90e96b8463d9cc4e. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair William Rieflin; Members William Rieflin (Chair); Clifford J. Friedman; Elizabeth Nabel. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_record:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Compensation: Chair Clifford J. Friedman; Members Clifford J. Friedman (Chair); William Rieflin. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_record:23. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Nominating and Governance: Chair not stated; Members Elizabeth Nabel. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_record:26. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Lyell Immunopharma, Inc.. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f9d431d4f573fa52a113a04a51bd131c3d0c5bd8f9b09708d52a918481152541. ## Entity Status - Public listing published. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f9d431d4f573fa52a113a04a51bd131c3d0c5bd8f9b09708d52a918481152541. ## Published Fact - US. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f9d431d4f573fa52a113a04a51bd131c3d0c5bd8f9b09708d52a918481152541. ## Committee Appointment - William Rieflin: chair, Audit. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Clifford J. Friedman: member, Audit. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Elizabeth Nabel: member, Audit. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Clifford J. Friedman: chair, Compensation. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:24. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - William Rieflin: member, Compensation. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:25. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. - Elizabeth Nabel: member, Nominating and Governance. Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:committee_appointment:27. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d. ## Security Listing - LYEL (NASDAQ). Claim: alpha:claim:company:c4cef1ca-c5d7-4446-8c3a-0cd3753768fb:security_listing:28. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:f9d431d4f573fa52a113a04a51bd131c3d0c5bd8f9b09708d52a918481152541. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:f9d431d4f573fa52a113a04a51bd131c3d0c5bd8f9b09708d52a918481152541: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/lyell-immunopharma-inc). - alpha:projection-evidence:document:77747deaf1944f2036e5e22289acc0440986a0c558d3ffba6acf67a2f0ad10d7: [Lyell Immunopharma, Inc. DEF 14A 2026-04-24](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:e4e1778b345e62bde7de98a4a5a81ef85040055ae32e0f8a8962d919b8db6bae: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:38d8832995f4cc3f87148dcbc7a1cdeec1e8280e4936cd4a2260980915404f64: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:a8feb7f4a9483c84c5f543aa45dcb5607d017ed17bd5def0c5925e2c84251646: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:9def3689e80e3c3526608efc7c40f31eadbf1dc0d21c3d7ee72fbd9074cc775e: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:3f372c75ae285ef6bb9b63df09092aa44753680a9d1dbfc41e3cfc53e87b372c: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:document:ed0feab478b28957f8d0a675bce18b4f21b00bcd083493cf90e96b8463d9cc4e: [LYEL DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). - alpha:projection-evidence:870945310071083464e71408d9d0b7c40606585cc91cde7039976ade0b66e45d: [Audit](https://www.sec.gov/Archives/edgar/data/1806952/000114036126016686/ny20068007x1_def14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/lyell-immunopharma-inc) - [Public Markdown](https://registry.alpha.ac/companies/lyell-immunopharma-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/lyell-immunopharma-inc?format=jsonld) - MCP resource: `alpha://companies/lyell-immunopharma-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-17T03:38:03.001241+00:00; recorded 2026-10-17T03:38:03.001241+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.